The United Kingdom and the United States have agreed to a major bilateral deal that will maintain no levies on UK medicine shipments entering the US market.
The Terms of the Pact
As part of the deal, the UK has committed to raise spending on drugs through the National Health Service (NHS). This move guarantees that duties on these vital exports will remain at zero for a timeframe of the next three years.
This agreement comes after recent statements to significantly raise tariffs on patented pharmaceutical imports, with figures mentioned reaching one hundred percent.
"This arrangement with the UK bolsters the global environment for new treatments and establishes long-overdue fairness to transatlantic drug exports," a release said.
Trade Impact
Drugs are one of the the United Kingdom's biggest exports to the US, which is by far the biggest buyer for large companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of the third quarter, the UK sold pharmaceutical products totaling billions to the US. This figure represented a significant portion of total UK exports in that timeframe.
"This deal secures work, stimulates capital expenditure and sets the stage for the UK to establish itself as a international leader for life sciences," a minister remarked.
Detailed British Pledges
The pact includes several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. In the past, refunds exceeded twenty percent.
Industry Background
The deal comes amid a long-running tension between the drug companies and the ministers over medicine costs and approval rates.
This friction were exacerbated by assertions that US consumers were charged several times more for the identical medicines than patients in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while major investments have been announced toward American operations.
A senior figure publicly accepted that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.
